BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36863695)

  • 1. A modified ELISA assay differentiates CCL20 locked dimers from wild-type monomers.
    Wu X; Clarke WR; Koplinski CA; Peterson FC; Dwinell MB; Wei G; Chao E; Huynh M; Yamada D; Volkman BF; Hwang ST
    J Immunol Methods; 2023 Apr; 515():113453. PubMed ID: 36863695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the CCR6/CCL20 Axis in Entheseal and Cutaneous Inflammation.
    Shi Z; Garcia-Melchor E; Wu X; Getschman AE; Nguyen M; Rowland DJ; Wilson M; Sunzini F; Akbar M; Huynh M; Law T; Raychaudhuri SK; Raychaudhuri SP; Volkman BF; Millar NL; Hwang ST
    Arthritis Rheumatol; 2021 Dec; 73(12):2271-2281. PubMed ID: 34081845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino terminal recognition by a CCR6 chemokine receptor antibody blocks CCL20 signaling and IL-17 expression via β-arrestin.
    Gómez-Melero S; García-Maceira FI; García-Maceira T; Luna-Guerrero V; Montero-Peñalvo G; Túnez-Fiñana I; Paz-Rojas E
    BMC Biotechnol; 2021 Jul; 21(1):41. PubMed ID: 34225700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.
    Homey B; Dieu-Nosjean MC; Wiesenborn A; Massacrier C; Pin JJ; Oldham E; Catron D; Buchanan ME; Müller A; deWaal Malefyt R; Deng G; Orozco R; Ruzicka T; Lehmann P; Lebecque S; Caux C; Zlotnik A
    J Immunol; 2000 Jun; 164(12):6621-32. PubMed ID: 10843722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model.
    Getschman AE; Imai Y; Larsen O; Peterson FC; Wu X; Rosenkilde MM; Hwang ST; Volkman BF
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12460-12465. PubMed ID: 29109267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCL20 and CCR6 axis in psoriasis.
    Furue K; Ito T; Tsuji G; Nakahara T; Furue M
    Scand J Immunol; 2020 Mar; 91(3):e12846. PubMed ID: 31692008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment.
    Kim TG; Byamba D; Wu WH; Lee MG
    Exp Dermatol; 2011 Oct; 20(10):855-7. PubMed ID: 21824198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of chemokine ligand 20 and chemokine receptor 6 in patients with sepsis: A case control study.
    Klaus DA; Seemann R; Roth-Walter F; Einwallner E; Motal MC; Tudor B; Lebherz-Eichinger D; Wiegele M; Krenn CG; Roth GA
    Eur J Anaesthesiol; 2016 May; 33(5):348-55. PubMed ID: 26771764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CC chemokine ligand 20 and CC chemokine receptor 6 mRNA in patients with psoriasis vulgaris.
    Wu Y; Li J
    J Huazhong Univ Sci Technolog Med Sci; 2004; 24(3):297-9. PubMed ID: 15315355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease.
    Dohlman TH; Chauhan SK; Kodati S; Hua J; Chen Y; Omoto M; Sadrai Z; Dana R
    Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4081-91. PubMed ID: 23702781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirubin attenuates IL-17A-induced CCL20 expression and production in keratinocytes through repressing TAK1 signaling pathway.
    Zhao J; Xie X; Di T; Liu Y; Qi C; Chen Z; Li P; Wang Y
    Int Immunopharmacol; 2021 May; 94():107229. PubMed ID: 33611057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer.
    Benkheil M; Van Haele M; Roskams T; Laporte M; Noppen S; Abbasi K; Delang L; Neyts J; Liekens S
    Exp Cell Res; 2018 Nov; 372(2):168-177. PubMed ID: 30287142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte attraction by CCL20 and its receptor CCR6 in humans and mice with pneumococcal meningitis.
    Klein M; Brouwer MC; Angele B; Geldhoff M; Marquez G; Varona R; Häcker G; Schmetzer H; Häcker H; Hammerschmidt S; van der Ende A; Pfister HW; van de Beek D; Koedel U
    PLoS One; 2014; 9(4):e93057. PubMed ID: 24699535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL20/CCR6 expression profile in pancreatic cancer.
    Rubie C; Frick VO; Ghadjar P; Wagner M; Grimm H; Vicinus B; Justinger C; Graeber S; Schilling MK
    J Transl Med; 2010 May; 8():45. PubMed ID: 20459729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.
    Giuliani N; Lisignoli G; Colla S; Lazzaretti M; Storti P; Mancini C; Bonomini S; Manferdini C; Codeluppi K; Facchini A; Rizzoli V
    Cancer Res; 2008 Aug; 68(16):6840-50. PubMed ID: 18703490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes.
    Liu Y; Lagowski JP; Gao S; Raymond JH; White CR; Kulesz-Martin MF
    J Invest Dermatol; 2010 May; 130(5):1384-90. PubMed ID: 20054338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptors in the pathogenesis and therapy of psoriasis.
    Mabuchi T; Chang TW; Quinter S; Hwang ST
    J Dermatol Sci; 2012 Jan; 65(1):4-11. PubMed ID: 22177422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
    Hirota K; Yoshitomi H; Hashimoto M; Maeda S; Teradaira S; Sugimoto N; Yamaguchi T; Nomura T; Ito H; Nakamura T; Sakaguchi N; Sakaguchi S
    J Exp Med; 2007 Nov; 204(12):2803-12. PubMed ID: 18025126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6
    Bouma G; Zamuner S; Hicks K; Want A; Oliveira J; Choudhury A; Brett S; Robertson D; Felton L; Norris V; Fernando D; Herdman M; Tarzi R
    Br J Clin Pharmacol; 2017 Sep; 83(9):1976-1990. PubMed ID: 28295451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.
    Goldminz AM; Suárez-Fariñas M; Wang AC; Dumont N; Krueger JG; Gottlieb AB
    JAMA Dermatol; 2015 Aug; 151(8):837-46. PubMed ID: 25946554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.